Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Baricitinib was effective in treating hair loss in adults with alopecia areata according to patient feedback.

This study reports the discovery of LX-38, a novel non-steroidal drug candidate that may offer safer treatment for conditions like Benign Prostatic Hyperplasia by avoiding hormonal side effects associated with current therapies.

This study found that approximately 85% of adults with severe alopecia areata who responded to baricitinib at 52 weeks maintained their improvement over a span of four years.

Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.

This study found that spironolactone was not independently associated with increased breast cancer recurrence and may be considered for treating alopecia in survivors.

In this review, spironolactone is highlighted for its emerging use in dermatology, particularly for treating androgen-mediated conditions like acne and hirsutism in susceptible females, though it requires careful monitoring for potential adverse effects.

This review discusses the benefits of β-sitosterol, a plant compound found in nuts and seeds, which may lower "bad" cholesterol and help prevent heart disease, cancer, and diabetes, but notes the lack of clinical studies on its safety and effectiveness in humans.

This study reports the development of novel 4-amido-Δ4,6-steroids as potential inhibitors of 5α-reductase, showing promising in vitro results for conditions like acne and benign prostatic cancer.

This study identified optimal parameters for extracting oil from Urtica dioica roots to maximize phytosterol content, using corn oil and a 1:5 raw material-extract ratio over a 6-hour maceration period.

This study found that two new progesterone derivatives showed higher antiandrogenic effects and 5α-reductase inhibition than finasteride in hamsters, particularly reducing seminal vesicle weight and flank organ size.

In this study on adolescents with severe alopecia areata, baricitinib treatment showed effective scalp, eyebrow, and eyelash regrowth after 52 weeks, benefiting both responders and partial or non-responders, potentially reducing the psychosocial impact of the disease.

This study identified enzymes responsible for regulating androgen action in the human prostate, suggesting that inhibiting AKR1C2 or RL-HSD may have therapeutic potential in androgen insufficiency or benign prostatic hyperplasia, respectively.

This study found that baricitinib, when administered consistently over three years, maintained its efficacy in patients with severe alopecia areata who responded by Week 52 with notable hair regrowth, indicated by a SALT score of ≤20.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

This study found that serum 3 alpha-Adiol-G levels in men are significantly associated with chest hair density and acne, indicating its role in reflecting androgen activity in peripheral tissues.

In this study, in silico analysis identified Saponin Re and Emodin as promising candidates for topical treatment of androgenetic alopecia, with Biochanin A having the most favorable safety profile among the tested compounds.

In this analysis, safety data from two clinical trials showed that baricitinib for severe alopecia areata had predictable side effects like infections and elevated CPK, with some serious adverse events noted at low incidence rates; no deaths were reported.

This study suggests that in human osteoblast-like cells, the 5alpha-reductase type 1 isozyme predominantly catalyzes the conversion of testosterone to DHT, which may play a role in bone homeostasis.

This study found that cortexolone 17α-propionate showed strong topical antiandrogenic activity, outperforming progesterone and several known antiandrogens, but lacked systemic antiandrogenic effects in animal models.

This study found that strigolactone biosynthesis and signaling components in soybean may interact with other hormone pathways, influencing soybean development and nodulation.

This study investigated the use of spironolactone in patients with estrogen-dependent cancers, aiming to determine if it is linked to increased cancer recurrence risk, but results are not reported.

In this study, patients with severe alopecia areata treated with baricitinib over 152 weeks experienced sustained patient-reported improvements in scalp, eyebrow, and eyelash hair regrowth, with higher responders observed in the 4mg dose group compared to the 2mg group.

The treatment slightly increased hair growth and was safe for most women.

This study found that strontium ranelate promotes cartilage regeneration in rats by enhancing chondrogenic differentiation of bone mesenchymal stem cells while inhibiting the Wnt/β-catenin signaling pathway.

This study found that the AabHLH112 transcription factor positively regulates the biosynthesis of β-caryophyllene, epi-cedrol, and β-farnesene in Artemisia annua.

This study identified novel 4-Amino-2H-benzo[h]chromen-2-one analogs as potent androgen receptor antagonists that show strong antiproliferative activity against prostate cancer cells, suggesting them as potential lead compounds for therapy development.

This study found that topical application of hair lotion containing 17α-estradiol may reduce androgenetic hair loss, as 63% of treated patients showed a decrease in telogen hairs compared to 37% in the control group.